bioRxiv · 10.1101/2025.10.29.685378
Microbiota-derived indole metabolites inhibit rotavirus infection in vitro and in vivo and in human infants
Abstract
Rotavirus (RV) is the leading cause of life-threatening gastroenteritis in children under five despite effective RV vaccines availability, necessitating novel protective strategies for high-risk populations. Gut microbiota can modulate RV susceptibility and vaccine immunogenicity, yet underlying mechanisms are poorly characterized. Here, we demonstrate that microbiota-derived indole metabolites confer protection against RV infection. In healthy adults, higher fecal indole-3-acetic acid (IAA) and indole-3-propionic acid (IPA) levels associated with reduced fecal RV shedding following challenge. In human intestinal enteroids (HIEs), IAA pre-treatment inhibited human RV Wa G1P[8] replication via the aryl hydrocarbon receptor (AhR) pathway. In mice, treatment with AhR agonist indole-3-carbinol (I3C) significantly reduced fecal shedding of murine RV strain EDIM-Cambridge. Finally, Zambian infants with active RV infection exhibited lower fecal IAA and IPA levels than age-matched healthy controls. These findings demonstrate that microbiota-derived AhR ligands consistently inhibit RV infection across three experimental models and hold promise for protecting at-risk pediatric populations.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Wirusanti, N. I., van Schajik, Y., Kim, J., Frempong, J. F., Simkhada, N., Fisher, S., Pucci, N., Piedade, G. J., Luchen, C. C., Chibuye, M., Simuyandi, M., Chisenga, C., Silwamba, S., Chibesa, K., Nzangwa, B. T., Kuntawala, D. H., Ramani, S., Mende, D., Baldridge, M. T., Sovran, B., Harris, V. C.. 2025-10-29. Microbiota-derived indole metabolites inhibit rotavirus infection in vitro and in vivo and in human infants. https://doi.org/10.1101/2025.10.29.685378
Cite the original work for its findings. Save a collection to share your selection of sources.